Fig. 1

Pharmacogenetic screening identified 95% of participants having the CYP2C9*1/*1 genotype (suggesting normal THC metabolism), with 5% at potential risk of developing THC acute negative effects including anxiety, hallucinations, paranoia, rapid heart rate and panic attacks. Furthermore, 35 and 25% had AKT1 genotypes suggesting intermediate risk (C/T genotype) or high risk (C/C genotype), respectively, for cannabis-induced psychosis; and 45 and 10% had COMT genotypes suggesting intermediate risk (Val/Met genotype) or high risk (Val/Val genotype), respectively for cannabis-induced neurocognitive impairment